Insulin cash price without insurance in 2026: the $35 programmes, the free routes and what pharmacies pay
Three makers publish a $35 monthly cash price for insulin, and two offer it free if income is low. Here is who each one excludes, when the offers end, and the gap between that $35 and what a pharmacy pays.
The answer, free routes first:
- Free if income is low: Sanofi gives a free 30-day supply of its insulin to US residents with no coverage for the product and household income under 400% of the federal poverty level, and Novo Nordisk's Patient Assistance Program is free for uninsured or Medicare patients up to the same 400% for insulins (maker pages, 26 October 2026).
- $35 a month cash price: Lilly ("all Lilly insulins are available for $35 a month whether you have commercial insurance or no insurance"), Novo Nordisk ("pay as little as $35" for up to 3 vials or 2 packs of pens) and Sanofi ($35 per 30-day supply of one or several of its insulins).
- Medicare and Medicaid: all three cash programmes exclude government-plan enrolees. Medicare Part D has its own cap, "no more than $35 for a one-month supply of each Part D-covered insulin product" (medicare.gov).
- Dates: Lilly's card "expires and savings end on 12/31/2026", so a 2027 price needs a fresh check in January.
Insulin is the drug where "what does it cost" has three different honest answers: the free route if your income is low, the $35 cash route, and the Medicare route, and which one is open depends on your coverage rather than the pharmacy. This page sets the three makers' published terms side by side, dated, and leaves the choice of insulin to the person who prescribes it. For other no-insurance prices see prescription drugs without insurance and our free prescription programmes guide.
- cash price, $35 a month
- free through the maker's assistance programme
- excluded or not readable
What does insulin cost without insurance in 2026?
For an eligible buyer, the published cash price from each of the three makers is $35 for a month's supply. Without the programmes, the lever is the price pharmacies pay: CMS's NADAC survey puts a pharmacy's acquisition cost at $61.52 for 1,000 units of Lantus and $52.20 for 1,000 units of Novolin R (U-100, as of 14 October 2026), before any dispensing margin. NADAC is not a shelf price, so the number only shows how thin a $35 cap is against the underlying cost, and it varies by product, as the figure further down shows.
What is the free route if your income is low?
Sanofi: "patients who meet certain eligibility requirements including those US residents with no product insurance coverage and have an annual income <400% of the Federal Poverty Level may qualify for 30-day supply of their insulin at NO COST" (teamingupfordiabetes.com, 26 October 2026). The application runs through Sanofi Patient Connection.
Novo Nordisk: its Patient Assistance Program is for "those with no insurance or Medicare" and is free "without any registration fees or monthly fees". For insulins the page sets household income at or below 400% of the federal poverty level, rules out private or commercial insurance, and rules out anyone "enrolled in or qualify for any other federal, state, or government program such as Medicaid" (novocare.com, 26 October 2026). For someone in immediate need, Novo's Immediate Supply is a one-time free supply of up to 3 vials or 2 packs of pens, described as "a short-term solution". The 400% line is set by the US poverty guidelines, published each year by HHS ASPE.
Lilly: Lilly Cares is Lilly's assistance foundation. Its own site returned an access error to RxGrab on 26 October 2026, so this page prints no Lilly Cares terms; OmniRx lists what it last confirmed on its Lilly Cares page, and the insulin assistance guide sets the three makers' free programmes side by side.
Which manufacturer programmes cap cash insulin at $35, and who is excluded?
Lilly: "all Lilly insulins are available for $35 a month whether you have commercial insurance or no insurance." Covered insulins named on the page are Basaglar, Humalog in its pen, cartridge, vial and mix forms, Lyumjev, Humulin N, Humulin 70/30, Humulin R, Humulin R U-500, unbranded insulin lispro and Rezvoglar. The cash card carries "a maximum of up to 14 prescription fills per calendar year for each Covered Insulin", and to use it you attest that "you are not enrolled in any state, federal, or government funded healthcare program". It "expires and savings end on 12/31/2026".
Novo Nordisk: MyInsulinRx is "pay as little as $35 for your monthly supply of any combination of Novo Nordisk covered insulin products", for people with commercial insurance or none. The $35 offer covers Fiasp, NovoLog, NovoLog Mix 70/30, Novolin N, Novolin R, Novolin 70/30 and Tresiba, up to 3 vials or 2 packs of pens (up to 35 mL) a month, with re-enrollment each calendar year. Awiqli has its own $55 option for up to 2 pens. The page defers the exclusions to a separate eligibility page that RxGrab did not read.
Sanofi: uninsured buyers "will pay no more than $35 total per 30-day supply for one or multiple Sanofi Insulins, when filled together each month". The programme "is not valid for prescriptions submitted for reimbursement, in whole or in part, to Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs". Sanofi names Lantus, Toujeo, Admelog, Apidra and Merilog among its brands, and publishes a phone line for eligibility questions, (833) 950-1304.
If you are uninsured or pay cash, all three makers will cap you at $35 a month; what separates them is the product list, the fill limits, and the expiry date.
Is human insulin cheaper, and do you need a prescription?
Novo Nordisk's page says that for people without insurance, human insulin "could be as low as $25/vial through several national pharmacy programs", and names Walmart ("$25 per vial") and CVS Health's Reduced Rx programme, which is for uninsured patients or those in a high-deductible plan. Walmart's own $4 Prescription Program list, effective 24 March 2025 and read in full on 26 October 2026, contains no insulin. Mark Cuban Cost Plus Drugs' pricing API (2,383 rows, read 26 October 2026) lists insulin pen needles but no insulin.
On prescriptions: in CMS's NADAC file Novolin R, Novolin N, Humulin N and one Humulin R listing carry the over-the-counter flag, and the analog insulins such as Lantus, NovoLog and Basaglar do not. The flag is CMS's classification, not a promise that a particular pharmacy will sell without a prescription, and Humulin R also appears in NADAC as a second listing, at $91.61 a mL, that is not flagged over the counter. Novo's own page frames human insulin as an option "for patients who have determined with their doctor that human insulin is an appropriate option for them", and this page does the same.
What do pharmacies pay for each insulin?
NADAC records what pharmacies pay to acquire a drug. For insulin it is quoted per mL, so the comparable measure is cost per 1,000 units. At the median, a pharmacy pays about $28.97 for the generic-named glargine, $52.20 for Novolin R and $61.52 for Lantus, and as much as $304.34 for Toujeo, which is U-300 and so holds three times the units per mL.
- human insulin
- maker brand, one of the three programmes
- unbranded or generic-named
- maker brand at 3.5 and 4.9 times its sibling (Basaglar, Toujeo)
The point of the gap is not that any insulin is the right or wrong choice. It is that a flat $35 programme price means the maker, not the buyer, absorbs very different acquisition costs, so the cash price tells you nothing about which product is cheaper to produce or to dispense. The generic-named glargine row has three NDCs and a range from $2.90 to $5.92 per mL (10th to 90th percentile), so even that product moves with the supplier. Civica, the non-profit, lists "long-acting insulin launch announced for 2026" on its timeline; its page shows no product, approval or price, so RxGrab treats it as announced, not available.
What if you have Medicare?
Medicare is the one route where the answer is a single federal rule. Medicare.gov states Part D coverage means "no more than $35 for a one-month supply of each Part B- and Part D-covered insulin product (other costs may apply)", and both Lilly's and Sanofi's pages repeat that the Part D cap applies independently of their cards. Their cash cards exclude Medicare enrolees. Novo's Patient Assistance Program is the one maker programme that names Medicare patients, with the 400% income test. For plan-by-plan detail see OmniRx's insulin assistance guide. RxGrab attaches no offer or enrolment link to any Medicare sentence.
Which route fits you
Uninsured, income under 400% of the poverty level
Apply to the free programme first
Sanofi gives a free 30-day supply; Novo's PAP is free; the $35 card is the fallback while you wait.
Uninsured, income above 400%
The maker's $35 card
Lilly, Novo and Sanofi all publish $35 a month for cash buyers; check the product is on the list.
On Medicare Part D
Your plan's $35 cap
The maker cash cards exclude you; Novo's PAP may apply under 400%.
Commercially insured with a high deductible
The commercial or cash card
Lilly, Novo and Sanofi cards all accept commercially insured buyers; limits differ by maker.
Medicaid, VA or TRICARE
Your own plan
All three maker programmes exclude government-plan enrolees; ask the plan about insulin cost-sharing.
1. Which insulin and which type (human or analog) has my prescriber written, and is a covered alternative acceptable to them? 2. Do I have no coverage, commercial coverage, Medicare, or Medicaid? (The maker cards exclude government plans.) 3. Is my household income under 400% of the federal poverty level? If yes, ask the maker's free programme first. 4. Is the $35 per month, per fill, or per product? (Sanofi: per 30 days for all Sanofi insulins filled together. Lilly: per fill, max 14 fills a year per insulin.) 5. When does the offer end? (Lilly's card: 12/31/2026. Novo: re-enroll every calendar year.) 6. Will the pharmacy accept the card, and does it need to be activated before I arrive?
Every programme, one table
| Programme | Price | Who qualifies or is excluded | Limits | Read |
|---|---|---|---|---|
| Lilly Insulin Value Program | $35 for a 1-month fill of a covered Lilly insulin | Commercial insurance or no insurance; excludes anyone enrolled in a state, federal or government-funded plan | Cash card: up to 14 fills a year per insulin; card expires 12/31/2026 | 26 Oct 2026 |
| "Pay as little as $35" a month | Commercial insurance or no insurance; full restrictions on a separate eligibility page | Up to 3 vials or 2 packs of pens (up to 35 mL); re-enroll each calendar year | 26 Oct 2026 | |
| Sanofi Insulins Savings Program | $35 per 30-day supply of one or several Sanofi insulins filled together | Uninsured, paying retail, or commercially insured; not valid with Medicare, Medicaid, VA, DOD or TRICARE | "Program maximums apply" | 26 Oct 2026 |
| Sanofi Patient Connection (free) | Free 30-day supply of insulin | US residents with no coverage for the product and income under 400% of the poverty level | Per the Sanofi savings page; apply for full terms | 26 Oct 2026 |
| Free | Uninsured or on Medicare; household income up to 400% of the poverty level for insulins; not commercially insured; not eligible if you qualify for Medicaid | Product list is in a linked PDF; some medicines left the PAP for 2026 | 26 Oct 2026 | |
| Free, one time | People at risk of rationing insulin with an immediate need | Up to 3 vials or 2 packs of pens | 26 Oct 2026 | |
| "$25 per vial" at Walmart pharmacies, per Novo Nordisk | Uninsured; no product named on the Novo page; Walmart's own page was behind a bot wall | Walmart's $4 list (effective 24 Mar 2025) has no insulin | 26 Oct 2026 | |
| Medicare Part D | No more than $35 for a one-month supply of each covered insulin | Medicare drug coverage | Other costs may apply | 26 Oct 2026 |
Terms are the makers' published programme terms on the date shown and can change without notice; each maker reserves the right to end its offer. Prices exclude taxes and fees where the maker says so.
Researchers, journalists and other sites can reuse the tables and figures under the RxGrab data licence.
How we built this page
How we built this page: we read Lilly's, Novo Nordisk's and Sanofi's own insulin programme pages, the Novo Nordisk assistance and human-insulin pages, Civica's home page, Medicare.gov's insulin page and Walmart's Prescription Program list on 26 October 2026, the Cost Plus Drugs pricing API the same day, and the CMS NADAC file as of 14 October 2026, and cite each figure where it appears. We did not buy insulin or use these programmes for this page; where a maker's page did not load or sends terms to another page, we say so rather than estimate. Nothing here is medical advice; do not change or substitute an insulin without your prescriber.
Frequently asked questions
How much does insulin cost without insurance in 2026?
Eligible uninsured buyers can pay $35 a month for insulin through each of the three makers: Lilly for all of its insulins, Novo Nordisk through MyInsulinRx (up to 3 vials or 2 packs of pens), and Sanofi ($35 per 30-day supply of one or several of its insulins). Programme terms read 26 October 2026; each maker can change or end its offer.
Can I get insulin free without insurance?
Possibly. Sanofi gives a free 30-day supply of its insulin to US residents with no coverage for the product and household income under 400% of the federal poverty level, and Novo Nordisk's Patient Assistance Program is free to eligible uninsured or Medicare patients with income up to 400% of the poverty level for insulins (maker pages, 26 October 2026).
Do the $35 insulin programmes work with Medicare or Medicaid?
No for the cash cards. Lilly excludes anyone enrolled in a state, federal or government-funded plan, and Sanofi's programme is not valid with Medicare, Medicaid, VA, DOD or TRICARE. Medicare Part D has its own cap of no more than $35 for a one-month supply of each covered insulin (medicare.gov, 26 October 2026).
When does Lilly's $35 insulin card expire?
Lilly's cash card page says the card "expires and savings end on 12/31/2026" and allows up to 14 prescription fills per calendar year for each covered insulin. Check Lilly's page in January for a 2027 price before relying on it.
Is human insulin cheaper, and can you buy it without a prescription?
Novo Nordisk says its human insulin is available at Walmart for $25 a vial. CMS's NADAC file flags Novolin R, Novolin N and Humulin N as over the counter, but that is CMS's classification, and whether a given pharmacy sells without a prescription is its own policy. Whether human insulin suits you is a decision for your prescriber.
Is there a generic or non-profit insulin I can buy?
Unbranded insulin lispro and insulin glargine-yfgn appear in CMS's NADAC data. Civica announced a long-acting insulin launch for 2026, but its page shows no product, approval or price, so RxGrab does not list it as available as of 26 October 2026.
Sources
- Lilly Insulin Value Program ($35 a month, exclusions, 12/31/2026 expiry)
- NovoCare: help with insulin costs (MyInsulinRx, PAP, Immediate Supply)
- NovoCare MyInsulinRx ($35, covered products, limits)
- NovoCare Patient Assistance Program (2026 eligibility)
- NovoCare human insulin options ($25 per vial at Walmart, CVS Reduced Rx)
- Sanofi Insulin Savings Program (Teaming Up for Diabetes) ($35 per 30 days, free supply under 400% FPL)
- Sanofi Patient Connection
- Medicare.gov: insulin ($35 cap)
- Civica Rx (long-acting insulin launch announced for 2026)
- Walmart Prescription Program list (effective 24 March 2025; no insulin)
- Mark Cuban Cost Plus Drugs pricing API (lists pen needles, no insulin)
- CMS NADAC weekly file (as of 14 October 2026)
- HHS ASPE: poverty guidelines (the 400% line)
- MedlinePlus: diabetes medicine and insulin (National Library of Medicine)
Join the list for prescription price-drop alerts
We have not started sending yet. Join the list and we will only email when we do.